MINAPHARM Pharmaceuticals (EGX: MIPH)
Egypt flag Egypt · Delayed Price · Currency is EGP
188.30
0.00 (0.00%)
At close: Dec 2, 2024

MINAPHARM Pharmaceuticals Statistics

Total Valuation

MINAPHARM Pharmaceuticals has a market cap or net worth of EGP 2.08 billion. The enterprise value is 4.50 billion.

Market Cap 2.08B
Enterprise Value 4.50B

Important Dates

The last earnings date was Thursday, November 28, 2024.

Earnings Date Nov 28, 2024
Ex-Dividend Date n/a

Share Statistics

MINAPHARM Pharmaceuticals has 11.06 million shares outstanding.

Current Share Class n/a
Shares Outstanding 11.06M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 1.66%
Owned by Institutions (%) n/a
Float 1.10M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.53
PB Ratio 0.52
P/TBV Ratio 0.62
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.63, with an EV/FCF ratio of -6.54.

EV / Earnings -16.46
EV / Sales 1.15
EV / EBITDA 11.63
EV / EBIT 30.15
EV / FCF -6.54

Financial Position

The company has a current ratio of 1.14, with a Debt / Equity ratio of 1.36.

Current Ratio 1.14
Quick Ratio 0.76
Debt / Equity 1.36
Debt / EBITDA 14.39
Debt / FCF -8.09
Interest Coverage 0.36

Financial Efficiency

Return on equity (ROE) is -5.71% and return on invested capital (ROIC) is 1.14%.

Return on Equity (ROE) -5.71%
Return on Assets (ROA) 0.97%
Return on Capital (ROIC) 1.14%
Revenue Per Employee 8.70M
Profits Per Employee -607,082
Employee Count 450
Asset Turnover 0.41
Inventory Turnover 2.43

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -20.30% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -20.30%
50-Day Moving Average 166.24
200-Day Moving Average 198.67
Relative Strength Index (RSI) 66.05
Average Volume (20 Days) 4,235

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, MINAPHARM Pharmaceuticals had revenue of EGP 3.92 billion and -273.19 million in losses. Loss per share was -24.69.

Revenue 3.92B
Gross Profit 1.01B
Operating Income 149.12M
Pretax Income -260.21M
Net Income -273.19M
EBITDA 343.18M
EBIT 149.12M
Loss Per Share -24.69
Full Income Statement

Balance Sheet

The company has 3.26 billion in cash and 5.56 billion in debt, giving a net cash position of -2.30 billion or -207.53 per share.

Cash & Cash Equivalents 3.26B
Total Debt 5.56B
Net Cash -2.30B
Net Cash Per Share -207.53
Equity (Book Value) 4.08B
Book Value Per Share 358.70
Working Capital 658.27M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 234.83 million and capital expenditures -921.86 million, giving a free cash flow of -687.03 million.

Operating Cash Flow 234.83M
Capital Expenditures -921.86M
Free Cash Flow -687.03M
FCF Per Share -62.10
Full Cash Flow Statement

Margins

Gross margin is 25.70%, with operating and profit margins of 3.81% and -6.67%.

Gross Margin 25.70%
Operating Margin 3.81%
Pretax Margin -6.64%
Profit Margin -6.67%
EBITDA Margin 8.76%
EBIT Margin 3.81%
FCF Margin -17.54%

Dividends & Yields

This stock pays an annual dividend of 1.65, which amounts to a dividend yield of 0.88%.

Dividend Per Share 1.65
Dividend Yield 0.88%
Dividend Growth (YoY) -41.07%
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield 0.88%
Earnings Yield -13.11%
FCF Yield -32.98%
Dividend Details

Stock Splits

The last stock split was on March 19, 2009. It was a forward split with a ratio of 10.

Last Split Date Mar 19, 2009
Split Type Forward
Split Ratio 10

Scores

MINAPHARM Pharmaceuticals has an Altman Z-Score of 0.91. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.91
Piotroski F-Score n/a